Abstract
Preeclampsia (PE) is one of the leading causes of maternal and perinatal mortality and morbidity. One of the main hallmarks observed in PE is impaired inflammation state. In the current study, we found that miR-125b was deregulated in placental tissues and plasma derived from PE patients, which suggest a potential association between this miRNA and the pathogenesis of PE. Overexpression of miR-125b significantly reduced SGPL1 expression, and luciferase assays confirmed that SGPL1 is a direct target of miR-125b. We also found that miR-125b enhanced IL-8 production by directly targeting sphingosine-1-phosphate lyase 1 (SGPL1), and this effect could be reversed by SGPL1 overexpression. In placentas derived from PE patients, a negative correlation of miR-125b and SGPL1 was observed, and IL-8 was validated to be increased in the circulation of PE patients. Our data demonstrated a critical role of miR-125b in IL-8 production and the development of PE.
Highlights
Preeclampsia (PE) is the leading cause of adverse health problems and morbidity in both the mother and the fetus worldwide[1], which is characterized by new occurrence of high blood pressure and proteinuria after the 20th week of pregnancies
We initially investigated miR-125b expression in the placenta tissues derived from PE patients using Real-time qPCR
We further tested miR-125b levels in plasma derived from PE patients and the controls
Summary
Preeclampsia (PE) is the leading cause of adverse health problems and morbidity in both the mother and the fetus worldwide[1], which is characterized by new occurrence of high blood pressure and proteinuria after the 20th week of pregnancies. MiR-125b Increased IL-8 Production in PE and analysis, decision to publish, or preparation of the manuscript
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
